Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

A clinical drug library screen identifies astemizole as an antimalarial agent NATURE CHEMICAL BIOLOGY Chong, C. R., Chen, X., Shi, L., O Liu, J., Sullivan, D. J. 2006; 2 (8): 415–16

Abstract

The high cost and protracted time line of new drug discovery are major roadblocks to creating therapies for neglected diseases. To accelerate drug discovery we created a library of 2,687 existing drugs and screened for inhibitors of the human malaria parasite Plasmodium falciparum. The antihistamine astemizole and its principal human metabolite are promising new inhibitors of chloroquine-sensitive and multidrug-resistant parasites, and they show efficacy in two mouse models of malaria.

View details for DOI 10.1038/nchembio806

View details for Web of Science ID 000239146800009

View details for PubMedID 16816845